MedTrace Logo

Evaluation of a MRI-based Prostate Cancer Screening Program

NCT03749993 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2023-05-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effort and resources (incl. costs) required to detect 20 clinically relevant prostate cancer (PCA) in a screening program based on bpMRI of the prostate.

Conditions

Interventions

OTHER

Screening

Use of bpMRI for opportunistic prostate cancer screening.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Cyrill Rentsch, MD PHD · University Hospital, Basel, Switzerland

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
46 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2023-04-01
Completion
2023-05-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03749993 on ClinicalTrials.gov